PDF factsheet
      Z

prevention in impaired fasting glucose for all type of patients, clinical trials results

error versus placebo
STOP-NIDDM (Chiasson), 2002
acarbose 100mg three times daily
versus
placebo
patients with impaired glucose tolerance (WHO 1985 criteria)double blind
Follow-up duration: 3.3 years
Canada, Germany, Austria, Nordic countries, Spain, Israel
insulin glargine versus placebo
GRACE - ORIGIN (glargine), 2012
insulin glargine (with a target fasting blood glucose level of <=95 mg per deciliter [5.3 mmol per liter])
versus
standard glycemic care alone
subject with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetesopen-label
lifestyle modification versus control
US-DDP (lifestyle) (Knowler), 2002
lifestyle-modification intervention
versus
placebo
nondiabetic patients with elevated glucose and high risk for diabetesopen
Follow-up duration: 2.8 years
metformin versus placebo
US-DPP (metformin) (Knowler), 2002
metformin 850mg twice daily
versus
placebo
nondiabetic patients with elevated glucose and high risk for diabetesdouble blind
Follow-up duration: 2.8 years
USA
n-3 fatty acid supplement versus placebo
GRACE - ORIGIN (n-3 fatty acid),
n-3 fatty acid supplemen
versus
placebo
subjects with known CV disease and/or CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetesdouble-blind
Follow-up duration: 4.9y (median)
nateglinide versus placebo
NAVIGATOR nateglinide, 2010
NCT00097786
nateglinide 60mg 3 times daily
versus
placebo
subjects with impaired glucose tolerance and either CV disease or CV risk factors double-blind
Follow-up duration: 5 years
40 countries
ramipril versus placebo
DREAM ramipril, 2006
NCT00095654
ramipril up to 15 mg daily
versus
placebo
patients with impaired fasting glucose or impaired glucose tolerance, or both, and no previous cardiovascular diseasedouble blind
Follow-up duration: 3 y (median)
21 countries
rosiglitazone versus placebo
DREAM rosiglitazone, 2006
NCT00095654
rosiglitazone 8 mg daily
versus
placebo
patients with impaired fasting glucose or impaired glucose tolerance, or bothdouble blind
Follow-up duration: 3 years (median)
21 countries
rosiglitazone and metformin versus placebo
CANOE, 2010
NCT00116932
rosiglitazone (2 mg) and metformin (500 mg) twice-daily
versus
placebo
patients with impaired glucose tolerance double-blind
Follow-up duration: 3.9y (median)
valsartan versus placebo
NAVIGATOR valsartan, 2010
NCT00097786
valsartan up to 160 mg daily
versus
placebo
subjects with impaired glucose tolerance and either CV disease or CV risk factorsdouble-blind
Follow-up duration: 5 years
40 countries
voglibose versus placebo
Voglibose Ph-3, 2009
UMIN 000001109-
voglibose 0.2 mg three times daily
versus
placebo
patients with impaired fasting glucosedouble blind
Follow-up duration: 4.01 years
Japan

  Options


in first

in second

  Filter